At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
NAMS NEWAMSTERDAM PHARMA CO NV
Pre-Mkt 12-22 05:01:24 EST
35.11
+1.21
+3.57%
High35.48Low34.04Vol961.55K
Open34.27D1 Closing33.90Amplitude4.26%
Mkt Cap3.98BTradable Cap2.27BTotal Shares113.39M
T/O33.66MT/O Rate1.49%Tradable Shares64.72M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

NewAmsterdam Pharma Company Nv : Stifel Raises Target Price to $50 From $44
THOMSON REUTERS  ·  12-16
NewAmsterdam Pharma Company Nv : Stifel Raises Target Price to $50 From $44
National Presto, Garrett Motion, and More Stocks See Action From Activist Investors -- Barrons.com
Dow Jones  ·  12-13
National Presto, Garrett Motion, and More Stocks See Action From Activist Investors -- Barrons.com
NewAmsterdam Pharma Grants Stock Options to New Hires Under 2024 Inducement Plan
Reuters  ·  12-06
NewAmsterdam Pharma Grants Stock Options to New Hires Under 2024 Inducement Plan
NewAmsterdam Pharma Executives to Join Major Investor Conferences
Reuters  ·  11-25
NewAmsterdam Pharma Executives to Join Major Investor Conferences
Stock Track | NewAmsterdam Pharma (NAMS) Soars 5% as Analysts Maintain Buy Ratings with High Price Targets
Stock Track  ·  11-10
Stock Track | NewAmsterdam Pharma (NAMS) Soars 5% as Analysts Maintain Buy Ratings with High Price Targets
RBC Capital Keeps Their Buy Rating on NewAmsterdam Pharma Company (NAMS)
TIPRANKS  ·  11-10
RBC Capital Keeps Their Buy Rating on NewAmsterdam Pharma Company (NAMS)
NewAmsterdam Pharma Grants Inducement Share Options to New Hire
Reuters  ·  11-08
NewAmsterdam Pharma Grants Inducement Share Options to New Hire
RBC Capital Remains a Buy on NewAmsterdam Pharma Company (NAMS)
TIPRANKS  ·  11-07
RBC Capital Remains a Buy on NewAmsterdam Pharma Company (NAMS)
RBC Raises Price Target on NewAmsterdam Pharma to $44 From $39, Keeps Outperform, Speculative Risk
MT Newswires Live  ·  11-06
RBC Raises Price Target on NewAmsterdam Pharma to $44 From $39, Keeps Outperform, Speculative Risk
NewAmsterdam Pharma Company Nv : Needham Raises Target Price to $46 From $40
THOMSON REUTERS  ·  11-06
NewAmsterdam Pharma Company Nv : Needham Raises Target Price to $46 From $40
NewAmsterdam Pharma Is Maintained at Buy by Needham
Dow Jones  ·  11-06
NewAmsterdam Pharma Is Maintained at Buy by Needham
NewAmsterdam Pharma Company Nv : Piper Sandler Raises Target Price to $60 From $37
THOMSON REUTERS  ·  11-05
NewAmsterdam Pharma Company Nv : Piper Sandler Raises Target Price to $60 From $37
NewAmsterdam Pharma Company NV reports results for the quarter ended September 30 - Earnings Summary
Reuters  ·  11-05
NewAmsterdam Pharma Company NV reports results for the quarter ended September 30 - Earnings Summary
NewAmsterdam Pharma reports Q3 revenue of $0.3 million and cash position of $756 million
Reuters  ·  11-05
NewAmsterdam Pharma reports Q3 revenue of $0.3 million and cash position of $756 million
Press Release: NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results
Dow Jones  ·  11-05
Press Release: NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results
NewAmsterdam Pharma Unveils Phase 3 Obicetrapib Data at AHA 2025 Sessions
Reuters  ·  10-30
NewAmsterdam Pharma Unveils Phase 3 Obicetrapib Data at AHA 2025 Sessions
NewAmsterdam Pharma’s REMBRANDT Trial: A Potential Game-Changer in Cardiovascular Treatment
TIPRANKS  ·  10-28
NewAmsterdam Pharma’s REMBRANDT Trial: A Potential Game-Changer in Cardiovascular Treatment
Entera Bio Presents Positive New Clinical Data from EB613 Phase 2 Trial Demonstrating Significant Bone Density Improvements in Early Postmenopausal Women
GlobeNewswire  ·  10-23
Entera Bio Presents Positive New Clinical Data from EB613 Phase 2 Trial Demonstrating Significant Bone Density Improvements in Early Postmenopausal Women
NewAmsterdam Pharma Coverage Assumed by HC Wainwright & Co. at Buy
Dow Jones  ·  10-20
NewAmsterdam Pharma Coverage Assumed by HC Wainwright & Co. at Buy
NewAmsterdam Pharma assumed with a Buy at H.C. Wainwright
TIPRANKS  ·  10-20
NewAmsterdam Pharma assumed with a Buy at H.C. Wainwright

Introduction

Company Name.
NEWAMSTERDAM PHARMA CO NV
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, develops oral and non-statin medicines for patients at high risk of cardiovascular disease. Its lead product candidate is obicetrapib, a next generation, oral, and low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in four ongoing Phase 3 and Phase 2b clinical trials as both a monotherapy and a combination therapy with ezetimibe for lowering LDL-C and preventing major adverse cardiovascular events (MACE). NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Issue price:
--